Pompini Agustina Sitompul

Pompini Agustina Sitompul

Auto-generated profile, based on publicly available information

Pompini Agustina Sitompul

Sulianti Saroso Infectious Disease, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Advances in Medicine
Verified
Journal Article
Open access
PDF file
PSPompini Agustina Sitompul
Pompini Agustina Sitompul
RIRoza Indriani
Roza Indriani
ARAdria Rusli
Adria Rusli
TSTiti Sundari
Titi Sundari
RRRosamarlina Rosamarlina
Rosamarlina Rosamarlina
VSVivi Setiawaty
Vivi Setiawaty
Background. Pneumonia is still a major global problem with high morbidity and mortality. The increasing number of pneumonia cases caused by bacteria, especially multidrug-resistant pathogens, increasing age of the population, patients with chronic disease (comorbid), and inappropriate antimicrobial therapy at initial administration make the treatment become less effective. These issues finally contribute to higher morbidity and mortality in cases of hospitalized pneumonia patients. Therefore, it is crucial to know the microbial pattern and select the therapy according to local antimicrobial sensitivity patterns. Method. A cross-sectional study was conducted for hospitalized pneumonia patients between January 2015 and December 2016 in Indonesia National Referral Infectious Disease Hospital. Data were collected from medical records to show patient characteristics, antimicrobial treatment data, culture examination, and bacterial sensitivity. Results. A total of 99 pneumonia patients required hospitalization and underwent sputum culture examination. The patients were mostly above 65 years old (32.3) and male (57.6). The most common comorbidities were pulmonary tuberculosis (21), and the others were heart failure, chronic obstructive pulmonary disease (COPD), and HIV/AIDS. Based on the sputum culture, fungi were identified in most specimens (56), while the bacteria identified were Klebsiella pneumoniae (14), Acinetobacter sp. (12), and Pseudomonas sp. (8). Third-generation cephalosporin, such as ceftriaxone (50), was commonly used as an antibiotic for pneumonia treatment. Conclusion. Most common bacteria isolated from sputum culture were Klebsiella pneumoniae which were more sensitive to the beta-lactam and aminoglycoside groups. The higher risk factors were age above 65 years old, being male, and having tuberculosis.

29 September 2022 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
PSPompini Agustina Sitompul
Pompini Agustina Sitompul
NMNina Mariana
Nina Mariana
EBErvan Budiman
Ervan Budiman
DTDian Wahyu Tanjung
Dian Wahyu Tanjung
BABetha Ariesanty
Betha Ariesanty
MSMohammad Syahril
Mohammad Syahril
Hospital workers were at high risk for SARS-CoV-2 infection and the first population with authorized access to the three doses of vaccination against SARS-CoV-2 antigen. The study was aimed to compare SARS-CoV-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso Infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-CoV-2 antibody levels measured by the Architect of SARS-CoV-2 IgG II Quant. There were 75 participants in the study, the median of anti SARS CoV-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, Interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p=1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). In this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection.